Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORGESIC vs CARISOPRODOL COMPOUND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NORGESIC is a combination of orphenadrine citrate, aspirin, and caffeine. Orphenadrine is a centrally acting muscle relaxant with anticholinergic properties; its exact mechanism is not fully understood, but it may act via central atropine-like effects and inhibition of reuptake of norepinephrine and serotonin. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, leading to analgesic, antipyretic, and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia via adenosine receptor antagonism.
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
1-2 tablets orally 2-4 times daily. Each tablet contains orphenadrine citrate 100 mg and acetaminophen 325 mg.
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
Terminal elimination half-life is 2–4 hours; clinical multiple dosing may require 4–6 hour intervals
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Orphenadrine is extensively metabolized in the liver via oxidative N-demethylation and hydroxylation; aspirin is hydrolyzed to salicylic acid, which is primarily metabolized in the liver by conjugation (glucuronidation and glycine conjugation) and oxidation; caffeine is metabolized in the liver via cytochrome P450 1A2 (CYP1A2) to paraxanthine, theobromine, and theophylline.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Primarily renal (70% as unchanged drug and metabolites; 10% as unchanged) and biliary (30%)
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
~90% bound to albumin and alpha-1-acid glycoprotein
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
1.5–2.0 L/kg; indicates extensive tissue distribution
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Oral: ~70% (first-pass metabolism reduces absolute bioavailability); Intramuscular: ~100%
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
GFR 30-59 m L/min: reduce dose by 50% (maximum 1 tablet twice daily). GFR <30 m L/min: avoid use due to risk of accumulation.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
Child-Pugh Class B: reduce dose by 50% (maximum 1 tablet twice daily). Child-Pugh Class C: contraindicated.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
Not recommended for patients under 18 years of age due to lack of safety and efficacy data.
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
Start with 1 tablet twice daily; titrate slowly due to increased risk of anticholinergic effects (confusion, urinary retention).
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
No FDA black box warning.
None
May impair mental and/or physical abilities required for driving or operating machinery due to anticholinergic effects (e.g., drowsiness, blurred vision),Use with caution in patients with glaucoma, prostatic hypertrophy, or gastrointestinal obstruction due to anticholinergic effects,Aspirin component increases risk of bleeding, particularly in patients with bleeding disorders or on anticoagulant therapy,Reye's syndrome risk in children and teenagers with viral infections,Hypersensitivity reactions including anaphylaxis may occur,Renal impairment may increase risk of salicylate toxicity
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
Hypersensitivity to any component,Peptic ulcer or gastrointestinal bleeding,Severe renal impairment (creatinine clearance <10 m L/min),Severe hepatic impairment,Bleeding disorders (e.g., hemophilia),Concurrent use of anticoagulants or antiplatelet drugs (relative),Children and teenagers with varicella or influenza-like symptoms (due to Reye's syndrome risk),Glaucoma (angle-closure), prostatic hypertrophy, or gastrointestinal obstruction (relative, due to anticholinergic effects)
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
Avoid alcohol. Take with food or milk to minimize GI irritation. No specific food interactions beyond alcohol and potential for increased gastric irritation with aspirin.
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
Norgesic contains orphenadrine citrate, aspirin, and caffeine. Aspirin: First trimester: possible increased risk of miscarriage and cardiac defects; third trimester: premature closure of ductus arteriosus and oligohydramnios; avoid in third trimester. Orphenadrine: limited human data; animal studies not sufficient; avoid in pregnancy unless benefit outweighs risk. Caffeine: considered low risk at moderate doses.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
Orphenadrine: excreted in breast milk; M/P ratio unknown; potential for anticholinergic effects in infant. Aspirin: excreted in breast milk; risk of Reye's syndrome if infant has viral illness; avoid breastfeeding while using aspirin. Caffeine: low levels in milk; generally considered safe in moderate amounts. Not recommended during breastfeeding.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
No standard dosing adjustments established. Avoid use in pregnancy, especially third trimester, due to aspirin component. If necessary, use lowest effective dose for shortest duration. Increased renal clearance in pregnancy may affect caffeine elimination, but no specific dose adjustment recommended.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
Norgesic (orphenadrine/aspirin/caffeine) is used for musculoskeletal pain. Orphenadrine has anticholinergic properties; use cautiously in elderly, glaucoma, or prostatic hypertrophy. May cause drowsiness and impair motor skills. Avoid in myasthenia gravis. Monitor for GI bleeding due to aspirin.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
Take with food or milk to reduce GI upset.,Avoid alcohol and other CNS depressants.,Do not drive or operate machinery until you know how this medication affects you.,Report signs of bleeding (bruising, black stools) or anticholinergic effects (dry mouth, blurred vision, constipation).,Do not exceed recommended dose; orphenadrine can cause serious anticholinergic toxicity.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORGESIC vs CARISOPRODOL COMPOUND, answered by our medical review team.
NORGESIC is a Muscle Relaxant that works by NORGESIC is a combination of orphenadrine citrate, aspirin, and caffeine. Orphenadrine is a centrally acting muscle relaxant with anticholinergic properties; its exact mechanism is not fully understood, but it may act via central atropine-like effects and inhibition of reuptake of norepinephrine and serotonin. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, leading to analgesic, antipyretic, and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia via adenosine receptor antagonism.. CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORGESIC and CARISOPRODOL COMPOUND depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORGESIC is: 1-2 tablets orally 2-4 times daily. Each tablet contains orphenadrine citrate 100 mg and acetaminophen 325 mg.. The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORGESIC and CARISOPRODOL COMPOUND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORGESIC is classified as Category C. Norgesic contains orphenadrine citrate, aspirin, and caffeine. Aspirin: First trimester: possible increased risk of miscarriage and cardiac defects; third trimester: premature clos. CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.